{"analyses":[{"ciLowerLimit":"0.80","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"1.45","estimateComment":"Back-transformed least squares mean difference and 90% confidence interval from mixed effects model performed on natural log-transformed values.","groupIds":["OG000"],"nonInferiorityComment":"Accumulation Ratio (Day 11 AUC0-24hr/Day 1 AUC0-24hr)","nonInferiorityType":"OTHER","paramType":"Accumulation ratio","paramValue":"1.08"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.33","upperLimit":"6.77","value":"5.41"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"title":"Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.48","upperLimit":"7.61","value":"5.84"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"title":"Day 11"}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"The AUC0-24hr of vorinostat in plasma on Days 1 and 11 is reported in participants who also received bortezomib.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants undergo ≤3 successive 21-day treatment cycles. During Cycle 1, participants receive vorinostat (400 mg QD on Days 1 through 14) + bortezomib (1.3 mg/m\\^2 IV on Days 1, 4, 8, and 11). If that dose is not well tolerated, during Cycle 2 participants receive vorinostat (400 mg QD on Days 1 through 14) + bortezomib (1.0 mg/m\\^2 IV on Days 1, 4, 8, and 11). If that dose is not well tolerated, during Cycle 3 participants receive vorinostat (300 mg QD on Days 1 through 14) + bortezomib (1.0 mg/m\\^2 IV on Days 1, 4, 8, and 11).","id":"OG000","title":"Vorinostat + Bortezomib"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"Participants with data available are included.","reportingStatus":"POSTED","timeFrame":"Predose and 0.8, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose on Days 1 and 11","title":"Area Under the Plasma Concentration-Time Curve From 0 to 24 Hours Postdose (AUC0-24hr) of Vorinostat Administered With Bortezomib on Days 1 and 11","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"µM*hr"}